Procurement for neutralising antibodies

Tender description

DHSC invites suppliers to provide information on neutralising antibodies and binding site, clinical trials on efficacy, safety for preventing or treating COVID-19 infection, dose&frequency, formats/routes for administering to patients, monitoring adverse affects, efficacy against SARS-CoV-2 variants, supply availability for 2021-2022 and future years and plans for regulatory approval in the UK, if not yet approved. Lot 1: The Department is interested in engaging with the emerging market prior to the publication of a contract notice to find innovative neutralising antibody COVID-19 therapies that could inform the specification of requirements, conditions of contract and commercial model. Further details of how suppliers may engage with the Department are included in section VI.3) (additional information) at the end of this notice. Additional information: Interested parties should submit questions via Atamis. Department welcomes discussions with interested parties on areas provision of a value for money solution for the UK tax payer;creating mechanisms for money solution for the UK tax payer; creating mechanisms (including but not limited to agreements) to secure long-term, guaranteed supply contracts with ‘step-in’ rights in future pandemics